Human trials exploring anti-aging medicines

Leonard Guarente, David A. Sinclair, Guido Kroemer

    Research output: Contribution to journalReview articlepeer-review

    46 Citations (Scopus)

    Abstract

    Here, we summarize the current knowledge on eight promising drugs and natural compounds that have been tested in the clinic: metformin, NAD+ precursors, glucagon-like peptide-1 receptor agonists, TORC1 inhibitors, spermidine, senolytics, probiotics, and anti-inflammatories. Multiple clinical trials have commenced to evaluate the efficacy of such agents against age-associated diseases including diabetes, cardiovascular disease, cancer, and neurodegenerative diseases. There are reasonable expectations that drugs able to decelerate or reverse aging processes will also exert broad disease-preventing or -attenuating effects. Hence, the outcome of past, ongoing, and future disease-specific trials may pave the way to the development of new anti-aging medicines. Drugs approved for specific disease indications may subsequently be repurposed for the treatment of organism-wide aging consequences.

    Original languageEnglish
    Pages (from-to)354-376
    Number of pages23
    JournalCell Metabolism
    Volume36
    Issue number2
    DOIs
    Publication statusPublished - 6 Feb 2024

    Keywords

    • age-related disease
    • autophagy
    • metformin
    • nicotinamide mononucleotide/NAD/sirtuins
    • senescence

    Cite this